News
CNSP
2.260
-0.21%
-0.005
Weekly Report: what happened at CNSP last week (0420-0424)?
Weekly Report · 2d ago
Weekly Report: what happened at CNSP last week (0413-0417)?
Weekly Report · 04/20 10:22
Weekly Report: what happened at CNSP last week (0406-0410)?
Weekly Report · 04/13 10:26
Weekly Report: what happened at CNSP last week (0330-0403)?
Weekly Report · 04/06 10:27
Weekly Report: what happened at CNSP last week (0323-0327)?
Weekly Report · 03/30 10:27
Weekly Report: what happened at CNSP last week (0316-0320)?
Weekly Report · 03/23 10:23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 03/18 12:05
Weekly Report: what happened at CNSP last week (0309-0313)?
Weekly Report · 03/16 10:23
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology
TipRanks · 03/11 13:02
CNS Pharmaceuticals launches new corporate growth strategy
TipRanks · 03/11 12:52
CNS Pharmaceuticals Launches Global Search For Neurology And Oncology Assets, Shifts Focus From Glioblastoma
Benzinga · 03/11 12:42
CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline
Reuters · 03/11 12:35
Weekly Report: what happened at CNSP last week (0302-0306)?
Weekly Report · 03/09 10:23
CNS Pharmaceuticals (CNSP) Receives a Buy from Maxim Group
TipRanks · 03/06 13:15
CNS Pharmaceuticals Files Initial Beneficial Ownership Statement for CTO Eric Faulkner
Reuters · 03/04 22:02
CNS Pharmaceuticals Files Initial Beneficial Ownership Statement for CFO Steve O’Loughlin
Reuters · 03/04 22:00
CNS Pharmaceuticals Appoints New Chief Medical Officer
TipRanks · 03/02 23:12
CNS Pharmaceuticals appoints Lynne Kelley as CMO
TipRanks · 03/02 13:42
CNS Pharmaceuticals names Lynne Kelley chief medical officer
Reuters · 03/02 13:25
Weekly Report: what happened at CNSP last week (0223-0227)?
Weekly Report · 03/02 10:22
More
Webull provides a variety of real-time CNSP stock news. You can receive the latest news about CNS Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About CNSP
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.